IPO registrations (S-1, F-1) · Registrants
Enveric Biosciences, Inc.
- SEC CIK
- 890821 · filings on EDGAR ↗
- Former names
- AMERI Holdings, Inc. (2015–2020); SPATIALIZER AUDIO LABORATORIES INC (1996–2015)
- Registration
- Form S-1, first filed 2000-04-17, last 2026-02-10; 9 initial registrations, 17 amendments
- Outcome
- Final prospectus filed 2017-11-20; declared effective 2017-06-30
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 245 FIRST STREET RIVERVIEW II 18TH FLOOR, Cambridge, MA 02142
- EIN
- 95-4484725
- Ticker
- ENVB (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Enveric Biosciences, Inc. on the corporate pages
On this site
- Form D issuer: Enveric Biosciences, Inc. EXACT (CIK (EXACT))
- SEC filer: AMERI Holdings, Inc. EXACT (CIK (EXACT))
Filings 51
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2000-04-17 | S-1/A | S-1/A (amendment) | SPATIALIZER AUDIO LABORATORIES INC | 0000950150-00-000320 ↗ |
| 2000-08-28 | S-1MEF | S-1MEF (added securities) | SPATIALIZER AUDIO LABORATORIES INC | 0000950150-00-000738 ↗ |
| 2002-05-29 | S-1 | S-1 (registration) | SPATIALIZER AUDIO LABORATORIES INC | 0000950148-02-001455 ↗ |
| 2002-07-30 | S-1/A | S-1/A (amendment) | SPATIALIZER AUDIO LABORATORIES INC | 0000950148-02-001775 ↗ |
| 2002-09-05 | S-1/A | S-1/A (amendment) | SPATIALIZER AUDIO LABORATORIES INC | 0000950148-02-002159 ↗ |
| 2002-10-30 | S-1/A | S-1/A (amendment) | SPATIALIZER AUDIO LABORATORIES INC | 0000950148-02-002546 ↗ |
| 2017-02-07 | S-1 | S-1 (registration) | AMERI Holdings, Inc. | 0001193805-17-000104 ↗ |
| 2017-04-18 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001193805-17-000652 ↗ |
| 2017-05-30 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001193805-17-000945 ↗ |
| 2017-06-22 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001193805-17-001150 ↗ |
| 2017-06-30 | EFFECT | EFFECT (declared effective) | AMERI Holdings, Inc. | 9999999995-17-001703 ↗ |
| 2017-09-18 | S-1 | S-1 (registration) | AMERI Holdings, Inc. | 0001193805-17-001663 ↗ |
| 2017-10-25 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001193805-17-003336 ↗ |
| 2017-10-27 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001193805-17-003362 ↗ |
| 2017-11-06 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001193805-17-003388 ↗ |
| 2017-11-08 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001193805-17-003408 ↗ |
| 2017-11-09 | EFFECT | EFFECT (declared effective) | AMERI Holdings, Inc. | 9999999995-17-002941 ↗ |
| 2017-11-17 | EFFECT | EFFECT (declared effective) | AMERI Holdings, Inc. | 9999999995-17-003011 ↗ |
| 2017-11-20 | 424B4 | 424B4 (final prospectus) | AMERI Holdings, Inc. | 0001193805-17-003513 ↗ |
| 2018-08-24 | S-1 | S-1 (registration) | AMERI Holdings, Inc. | 0001140361-18-036924 ↗ |
| 2018-09-25 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001140361-18-039056 ↗ |
| 2018-10-22 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001140361-18-040993 ↗ |
| 2018-10-23 | S-1/A | S-1/A (amendment) | AMERI Holdings, Inc. | 0001140361-18-041092 ↗ |
| 2018-10-23 | EFFECT | EFFECT (declared effective) | AMERI Holdings, Inc. | 9999999995-18-002691 ↗ |
| 2018-11-13 | S-1 | S-1 (registration) | AMERI Holdings, Inc. | 0001140361-18-042978 ↗ |
| 2018-11-21 | EFFECT | EFFECT (declared effective) | AMERI Holdings, Inc. | 9999999995-18-002958 ↗ |
| 2019-11-19 | EFFECT | EFFECT (declared effective) | AMERI Holdings, Inc. | 9999999995-19-002607 ↗ |
| 2020-11-12 | EFFECT | EFFECT (declared effective) | AMERI Holdings, Inc. | 9999999995-20-003141 ↗ |
| 2021-04-07 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-21-001321 ↗ |
| 2021-07-09 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-21-002714 ↗ |
| 2021-08-06 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-21-003087 ↗ |
| 2022-08-11 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-22-002349 ↗ |
| 2023-11-08 | S-1 | S-1 (registration) | Enveric Biosciences, Inc. | 0001493152-23-039794 ↗ |
| 2023-12-01 | S-1/A | S-1/A (amendment) | Enveric Biosciences, Inc. | 0001493152-23-043417 ↗ |
| 2023-12-05 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-23-003547 ↗ |
| 2023-12-06 | 424B4 | 424B4 (final prospectus) | Enveric Biosciences, Inc. | 0001493152-23-043862 ↗ |
| 2024-01-22 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-24-000170 ↗ |
| 2024-09-04 | S-1 | S-1 (registration) | Enveric Biosciences, Inc. | 0001493152-24-035018 ↗ |
| 2024-09-11 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-24-002802 ↗ |
| 2024-09-12 | 424B4 | 424B4 (final prospectus) | Enveric Biosciences, Inc. | 0001493152-24-035972 ↗ |
| 2025-01-14 | S-1 | S-1 (registration) | Enveric Biosciences, Inc. | 0001493152-25-002214 ↗ |
| 2025-01-30 | S-1/A | S-1/A (amendment) | Enveric Biosciences, Inc. | 0001493152-25-004213 ↗ |
| 2025-01-30 | S-1/A | S-1/A (amendment) | Enveric Biosciences, Inc. | 0001493152-25-004292 ↗ |
| 2025-01-30 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-25-000244 ↗ |
| 2025-02-03 | 424B4 | 424B4 (final prospectus) | Enveric Biosciences, Inc. | 0001493152-25-004528 ↗ |
| 2025-04-17 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-25-001139 ↗ |
| 2025-12-08 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-25-003576 ↗ |
| 2025-12-30 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-25-003969 ↗ |
| 2026-02-10 | S-1 | S-1 (registration) | Enveric Biosciences, Inc. | 0001493152-26-005852 ↗ |
| 2026-02-17 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-26-000616 ↗ |
| 2026-04-29 | EFFECT | EFFECT (declared effective) | Enveric Biosciences, Inc. | 9999999995-26-001390 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| GOTTLIEB JAY | Director,Officer,TenPercentOwner; DirectorOther; Director,TenPercentOwner; TenPercentOwner | Chief Executive Officer | 6 | 2007–2013 | |
| SCHNEIDER GREGGORY A | Director; Director,Officer,TenPercentOwner; DirectorOther | Chief Financial Officer | 6 | 2008–2013 | |
| Pearce Michael Cooper | Director | 1 | 2008 | ||
| Eberwein Jeffrey E. | Director,Officer,TenPercentOwner; Director,TenPercentOwner; TenPercentOwner | Chairman, President, CEO, CFO | 60 | 2013–2018 | |
| Lone Star Value Investors GP LLC | TenPercentOwner; TenPercentOwnerOther | 59 | 2014–2018 | ||
| Lone Star Value Investors LP | TenPercentOwner; TenPercentOwnerOther | 59 | 2014–2018 | ||
| Hartley Kyle | Director | 1 | 2014 | ||
| Bible Hannah M. | Director | 1 | 2014 | ||
| DeRosa William Thomas Jr. | Director | 1 | 2014 | ||
| Lone Star Value Management LLC | TenPercentOwner; TenPercentOwnerOther | 57 | 2015–2018 | ||
| Devanur Giri | Director,Officer,TenPercentOwner; Officer; TenPercentOwner | President & CEO | 4 | 2015–2018 | |
| Devanur Srinidhi | Director,Officer,TenPercentOwner | Exec. Vice Chairman | 2 | 2015–2016 | |
| Jagannath Brunda | Officer | Vice President - Finance | 1 | 2015 | |
| Angelis Dimitrios | Director | 9 | 2015–2018 | ||
| Langer Arthur M | Director | 8 | 2015–2018 | ||
| Pearse Robert G. | Director | 8 | 2015–2018 | ||
| Rosenberg Robert Alan | Director | 3 | 2015–2017 | ||
| O'Donnell Edward | Officer | Chief Financial Officer | 2 | 2016 | |
| Rai Dhruwa N | Director | 10 | 2016–2018 | ||
| Balakrishnan Venkatraman | Director | 7 | 2016–2018 | ||
| Patel Viraj J | Officer | Chief Financial Officer | 3 | 2017–2018 | |
| Lone Star Value Co-Invest I, LP | Other; TenPercentOwner | 10 | 2017–2018 | ||
| Kelton Brent | Officer | Chief Executive Officer | 5 | 2018–2019 | |
| LUCI DAVID P | Director | 2 | 2018 | ||
| Shad James | Director | 2 | 2018 | ||
| Shawah Robert G. | Director | 2 | 2018 | ||
| Kostiner Barry | Officer | Chief Financial Officer | 2 | 2018 | |
| Lokesh Sikaria Trust Dated 12/14/2012 | TenPercentOwner | 2 | 2018 | ||
| Sikaria Chanda | TenPercentOwner | 2 | 2018 | ||
| Sikaria Family 2008 Revocable Trust Dated 02/28/2008 | TenPercentOwner | 2 | 2018 | ||
| Sikaria Lokesh | TenPercentOwner | 2 | 2018 | ||
| Sukumaran Thoranath | Director | 1 | 2018 | ||
| Johnson David Ian | Director,Officer | CEO and Chairman | 2 | 2021 | |
| Kanubaddi Avani | Officer | Chief Operating Officer; President and COO | 4 | 2021–2023 | |
| Kegler George A. | Director | 5 | 2021–2026 | ||
| Mayer Solomon | Director | 2 | 2021 | ||
| Schabacker Marcus | Director | 5 | 2021–2026 | ||
| TOP Invest LLC | TenPercentOwner | 1 | 2021 | ||
| Van Buiten John | Officer | Chief Financial Officer | 2 | 2021 | |
| Wilkins Robert G. | Officer | Chief Medical Officer | 1 | 2021 | |
| LIND DOUGLAS | Director | 2 | 2021 | ||
| Ward Carter Julian | Officer | Chief Financial Officer | 2 | 2021–2022 | |
| Thompson Bradley George | Director | 2 | 2021 | ||
| Tucker Joseph Edward | Director,Officer | Chief Executive Officer; CHIEF EXECUTIVE OFFICER | 10 | 2021–2026 | |
| Facchini Peter J. | Officer | Chief Innovation Officer; CHIEF INNOVATION OFFICER; Chief Scientific Officer | 8 | 2021–2026 | |
| Hagel Jillian Marie | Officer | Chief Technical Officer; Chief Technology Officer; Vice President of Innovation | 4 | 2021–2023 | |
| WEBB MICHAEL D | Director | 4 | 2022–2026 | ||
| O'NEIL BEVIN | Director | 1 | 2022 | ||
| PASQUALONE FRANK | Director | 5 | 2022–2026 | ||
| Dickey Robert IV | Officer | Chief Financial Officer | 1 | 2022 | |
| Coveney Kevin Michael | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER | 7 | 2023–2026 | |
| DeWitt Sheila | Director | 4 | 2024–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-05-04 | Enveric Biosciences, Inc. | Biotechnology | $5,000,002 | $5,000,002 | 4 | 1 |
| 2026-02-11 | Enveric Biosciences, Inc. | Biotechnology | $1,450,017 | $1,450,017 | 5 | 1 |
| 2025-12-23 | Enveric Biosciences, Inc. | Biotechnology | $106,598 | $106,598 | 15 | 1 |
| 2025-10-03 | Enveric Biosciences, Inc. | Pharmaceuticals | Indefinite | $0 | 12 | 1 |
| 2022-08-05 | Enveric Biosciences, Inc. | Pharmaceuticals | $12,780,000 | $12,780,000 | 2 | 2 |
| 2021-02-24 | Enveric Biosciences, Inc. | Pharmaceuticals | $8,398,625 | $0 | 6 | 1 |
| 2021-01-20 | Enveric Biosciences, Inc. | Pharmaceuticals | $8,249,959 | $0 | 6 | 1 |
| 2018-08-02 | AMERI Holdings, Inc. | Business Services | $6,600,000 | $6,600,000 | 4 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.